Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-1: VY-AADC02 in Parkinson's Disease
NCT03562494Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2018
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ezaladcigene resoparvovec in Parkinson's disease (PD) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2018; status: completed.
02
Drugs
ezaladcigene resoparvovec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03562494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562494.